In addition, combining anti-EGFR antibodies with neoadjuvant chemotherapy has been shown to remodel the tumor microenvironment by increasing cytotoxic T cells and decreasing immunosuppressive regulatory T cells and M2 macrophages, resulting in higher remission rates [25]. The gene discussed is EGFR; the disease is neoplasm.